We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Groupe Crit | EU:CEN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.40 | 0.54% | 74.00 | 73.80 | 75.60 | 75.60 | 73.80 | 75.60 | 2,943 | 02:01:03 |
Hot Features
Premium
RNS Number:3911T
CeNeS Pharmaceuticals PLC
17 December 2003
CENES PHARMACEUTICALS PLC ("the Company")
HOLDING IN COMPANY
The Company has been notified that following the Company's acquisition of
TheraSci Limited announced on 24 November 2003, Avlar Bioventures Fund II
Limited Partnership has an interest in 22,786,596 ordinary shares of 1p each in
the Company, representing 9.1 per cent. of the current issued share capital of
the Company.
Further information
Neil Clark, CeNeS Pharmaceuticals plc 01223 266 466
17 December 2003
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUBUNROBRUAAA
1 Year Groupe Crit Chart |
1 Month Groupe Crit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
